The potential in vitro activities aligns with high affinity for HDM2 critical for breast and prostate cancers. HDM2 inhibitors (e.g., Nutlin-3, RG7112, Idasanutlin) are being explored as cancer treatments (Alaseem, 2023), particularly in tumors with wild-type p53, as they can restore p53 function and induce apoptosis in cancer cells. Here, MDM2 is linked to prostate cancer.